BioSig Tech is at the forefront of medical technology innovation with its groundbreaking PURE EP™ System. In this article, we delve into the revolutionary capabilities of BioSig Tech's cutting-edge product, exploring how it works, its myriad benefits, and its potential to reshape the landscape of cardiac electrophysiology.
BioSig Tech is a leading digital signal processing company
that specializes in developing cutting-edge solutions for the medical industry.
With a unique combination of expertise in medical engineering, intellectual
property, and workflow, the company has created a groundbreaking product called
the PURE EP™ System that promises to revolutionize cardiac electrophysiology.
In this article, we'll take a closer look at BioSig Tech and
their innovative product, the PURE EP™ System. We'll examine how the system works,
its key features and benefits, and how it's poised to change the landscape of
cardiac electrophysiology.
Atrial fibrillation causes more than 750,000
hospitalizations in the US each year, resulting in about $6 billion in
healthcare spending annually. BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform
designed to improve signal fidelity and uncover the full range of ECG and
intra-cardiac signals.
The company's first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying, filtering,
measuring and calculating, displaying, recording and storing of
electrocardiographic and intracardiac signals for patients undergoing
electrophysiology (EP) procedures in an EP laboratory.
BioSig’s non-invasive computerized technology, the PURE EP
System, aims to drive procedural efficiency and efficacy in electrophysiology.
The system provides essential diagnostic signals with high clinical value in
all cardiac ablations that treat irregular heartbeats or arrhythmias.
Recently, BioSig Tech
has increased its patient case goal to at least 1,500 procedures by the end of
2021. Previously, the company had announced its target to complete 1,000
patient cases in 2021, having delivered 425 procedures by the end of 2020.
The company said it is currently conducting patient cases in
nine medical centers across the country. Texas Cardiac Arrhythmia Institute at
St. David’s Medical Center in Austin, Texas, its first commercial customer,
continues to be the biggest user of the technology with over 300 patient cases
conducted to date.
Mayo Clinic Florida Campus and the University of
Pennsylvania are the second and third largest patient case drivers with 130 and
112 cases, respectively. And more than 800 procedures have been conducted with
the PURE EP System in the last 18 months.
BioSig noted that one in 18 Americans suffers from cardiac
arrhythmia. Atrial fibrillation is the most common arrhythmia type, affecting
over 33 million people worldwide, including over 6 million in the US.
“Patient case volume is one of the leading indications of
physician utilization of our technology,” said BioSig CEO Kenneth Londoner in a
statement. “We see steady procedural growth in almost all of our centers, which
we believe will turn into commercial revenues. This case growth, combined with
the consistently positive customer feedback, positions us well to deliver on
our target of 20 installation sites by the end of 2021.”
BioSig Technologies (NASDAQ: BSGM) is a medical technology company which designs and commercializes an innovative signal processing platform. Bio Sig’s signal processing platform is aimed to uncover the full range of ECG and intra-cardiac signals and to improve signal fidelity.
BioSig Technologies
has recently announced that during EPLive 2020, the fifth international symposium on complex
arrhythmias, its
first product, the PURE EP system, would be featured in
several live cases broadcast.
